Antipsychotic exposure prior to acute myocardial infarction in patients with serious mental illness

Acta Psychiatrica Scandinavica

Volumn 131, Issue 3, 2015, Pages 213-222

  Wu, S I ^a,b   Kao, K L ^c   Chen, S C ^d   Juang, J J M ^e   Lin, C J ^a   Fang, C K ^a   Wu, C S ^c   Dewey, M ^f   Prince, M J ^f   Stewart, R ^f  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b MACKAY MEDICAL COLLEGE   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acute myocardial infarction; Antipsychotic; Bipolar disorder; Schizophrenia; Serious mental illness

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PIMOZIDE; PIPAMPERONE; PROCHLORPERAZINE; PROMAZINE; QUETIAPINE; SULPIRIDE; THIORIDAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BIPOLAR DISORDER; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; NATIONAL HEALTH INSURANCE; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; VULNERABLE POPULATION; AGED; CASE CONTROL STUDY; CHEMICALLY INDUCED; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTOR; TAIWAN;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CASE-CONTROL STUDIES; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; SCHIZOPHRENIA; TAIWAN;

EID: 84922620260     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12345     Document Type: Article

References (50)

1. Kisely S, Smith M, Lawrence D, Maaten S. Mortality in individuals who have had psychiatric treatment: population-based study in Nova Scotia. Br J Psychiatry 2005;187:552-558.
2. Hoang U, Goldacre MJ, Stewart R. Avoidable mortality in people with schizophrenia or bipolar disorder in England. Acta Psychiatr Scand 2013;127:195-201.
3. Chang CK, Hayes RD, Perera G et al. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS One 2011;6:e19590.
4. Laursen TM, Wahlbeck K, Hallgren J et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One 2013;8:e67133.
5. Lawrence DM, Holman CD, Jablensky AV, Hobbs MS. Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998. Br J Psychiatry 2003;182:31-36.
6. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29:697-701.
7. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003;183:534-539.
8. Robson D, Gray R. Serious mental illness and physical health problems: a discussion paper. Int J Nurs Stud 2007;44:457-466.
9. Dickerson FB, Brown CH, Kreyenbuhl JA et al. Obesity among individuals with serious mental illness. Acta Psychiatr Scand 2006;113:306-313.
10. von Hausswolff-Juhlin Y, Bjartveit M, Lindstrom E, Jones P. Schizophrenia and physical health problems. Acta Psychiatr Scand 2009;119(Suppl 438):15-21.
11. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007;116:317-333.
12. Brauer R, Douglas I, Smeeth L. The association between antipsychotic agents and the risk of myocardial infarction: a systematic review. Br J Clin Pharmacol 2011;72:871-878.
13. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 2011;68:609-616.
14. Leonard CE, Freeman CP, Newcomb CW et al. Antipsychotics and the risks of sudden cardiac death and all-cause death: cohort studies in medicaid and dually-eligible medicaid-medicare beneficiaries of five states. J Clin Exp Cardiolog 2013;Suppl 10:1-9.
15. Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 2005;20:243-251.
16. Wang PS, Schneeweiss S, Setoguchi S et al. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol 2007;27:707-710.
17. Wang S, Linkletter C, Dore D, Mor V, Buka S, Maclure M. Age, antipsychotics, and the risk of ischemic stroke in the Veterans Health Administration. Stroke 2012;43:28-31.
18. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008;337:a1227.
19. Pariente A, Fourrier-Reglat A, Ducruet T et al. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med 2012;172:648-653; discussion 654-645.
20. Rochon PA, Normand SL, Gomes T et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008;168:1090-1096.
21. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 1996;94:3123-3129.
22. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 2004;192:19-27.
23. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 2007;64:242-249.
24. Barak Y, Baruch Y, Mazeh D, Paleacu D, Aizenberg D. Cardiac and cerebrovascular morbidity and mortality associated with antipsychotic medications in elderly psychiatric inpatients. Am J Geriatr Psychiatry 2007;15:354-356.
25. Jerrell JM, McIntyre RS. Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications. Hum Psychopharmacol 2007;22:361-364.
26. Penttinen J, Valonen P. Use of psychotropic drugs and risk of myocardial infarction: a case-control study in Finnish farmers. Int J Epidemiol 1996;25:760-762.
27. Thorogood M, Cowen P, Mann J, Murphy M, Vessey M. Fatal myocardial infarction and use of psychotropic drugs in young women. Lancet 1992;340:1067-1068.
28. Nakagawa S, Pedersen L, Olsen ML, Mortensen PB, Sorensen HT, Johnsen SP. Antipsychotics and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. J Intern Med 2006;260:451-458.
29. NHIRD. National Health Insurance Research Database, Taiwan. Introduction to the National Health Insurance Research Database (NHIRD), Taiwan (http://www.nhri.org.tw/nhird/en/index.htm). Accessed 20 January 2010. 2006.
30. NHIRD. National Health Insurance Research Database, Taiwan. Longitudinal Health Insurance Database (LHID), Taipei (http://w3.nhri.org.tw/nhird//en/Data_Subsets.html#S3). Accessed 20 January 2010. 2008.
31. Wu SI, Chen SC, Juang JJ et al. Diagnostic procedures, revascularization, and inpatient mortality after acute myocardial infarction in patients with schizophrenia and bipolar disorder. Psychosom Med 2013;75:52-59.
32. Chang L. A study of validation on comorbidity derived from claims data [Master thesis]: National Yang-Ming University; 2004.
33. Wu CY, Chan FK, Wu MS et al. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Gastroenterology 2010;139:1165-1171.
34. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991;133:144-153.
35. Loughnan ME, Nicholls N, Tapper NJ. Demographic, seasonal, and spatial differences in acute myocardial infarction admissions to hospital in Melbourne Australia. Int J Health Geogr 2008;7:42.
36. World Health Organization, Collaborating Centre for Drug Statistic Methodology. Guidelines for ATC classification and DDD assignment. Oslo: World Health Organization, 2009.
37. Wu CS, Wang SC, Cheng YC, Gau SS. Association of cerebrovascular events with antidepressant use: a case-crossover study. Am J Psychiatry 2011;168:511-521.
38. Meltzer HY. What's atypical about atypical antipsychotic drugs? Curr Opin Pharmacol 2004;4:53-57.
39. Wu CS, Wang SC, Gau SS, Tsai HJ, Cheng YC. Association of stroke with the receptor-binding profiles of antipsychotics-a case-crossover study. Biol Psychiatry 2013;73:414-421.
40. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999;60(Suppl 10):5-14.
41. Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001;53:319-356.
42. O'Mahony C, Elliott PM. Prevention of sudden cardiac death in hypertrophic cardiomyopathy. Heart 2014;100:254-260.
43. Yamada S, Akita H, Kanazawa K et al. T102C polymorphism of the serotonin (5-HT) 2A receptor gene in patients with non-fatal acute myocardial infarction. Atherosclerosis 2000;150:143-148.
44. Tiihonen J, Lonnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620-627.
45. Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 2012;69:476-483.
46. Manu P, Kane JM, Correll CU. Sudden deaths in psychiatric patients. J Clin Psychiatry 2011;72:936-941.
47. Chuang DM, Wang Z, Chiu CT. GSK-3 as a target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke. Front Mol Neurosci 2011;4:15.
48. Liao DL, Yang JY, Lee SM, Chen H, Tsai SJ. Smoking in chronic schizophrenic inpatients in Taiwan. Neuropsychobiology 2002;45:172-175.
49. Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999;81:380-386.
50. Leucht S, Tardy M, Komossa K et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012;379:2063-2071.